Research papers

Search for

Mechanisms research papers

Animal models of Parkinson's disease: Limits and relevance to neuroprotection studiesIn this position article, the authors present the relevance of both pathogenic and etiologic models as well as the concept of clinically relevant designs that, we argue, should be utilized in the preclinical development phase of new neuroprotective therapies before embarking into clinical trials. 15 January 2013
Parkinson's disease: Evidence for environmental risk factorsThis article reviews environmental factors that may increase the risk of PD, as well as the evidence behind those factors. Enough evidence exists to suggest that age has a causal relationship to PD. 15 January 2013
Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson diseaseThis ALDH model for PD etiology may help explain the selective vulnerability of dopaminergic neurons in PD and provide a potential mechanism through which environmental toxicants contribute to PD pathogenesis. 08 January 2013
IRC-082451, a Novel Multitargeting Molecule, Reduces L-DOPA-Induced Dyskinesias in MPTP Parkinsonian PrimatesThe data demonstrates the antidyskinetic efficacy of IRC-082451 in a primate model of PD with motor complications and opens the way to the clinical application of this treatment for the management of LIDs. 03 January 2013
Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegenerationTogether these data support a neuroprotective role of endogenous urate in dopaminergic neurons and strengthen the rationale for developing urate-elevating strategies as potential disease-modifying therapy for PD. 02 January 2013
Serum Uric Acid in Patients with Parkinson's Disease and Vascular Parkinsonism: A Cross-Sectional StudyResults strongly imply that either low serum UA level is a deteriorative predictor or that serum UA level serves as an indirect biomarker of prediction in PD but not in VP patients. 01 January 2013
Existing and emerging mitochondrial-targeting therapies for altering Parkinson's disease severity and progressionBoth drug-related and gene-based therapeutic approaches are discussed, with evidence presented from both animal modelling studies as well as product assessments undergoing various phases of clinical trial progression. 01 January 2013
Association of nicotine dependence susceptibility gene, CHRNA5, with Parkinson's disease age at onset: Gene and smoking status iPreliminary results suggest that the ND risk variant, rs588765, has a protective effect in PD, and is associated with later AAO, but only when the individual was previously exposed to nicotine. This may be explained by modulating the neuroprotective effect of chronic nicotine exposure against striatal dopaminergic damage. Further validation studies in additional populations are required. 01 January 2013
Low serum uric acid concentration in Parkinson's disease in southern SpainThis study produced consistent findings that UA might have a protective effect against Parkinson's disease and could influence its clinical progression. 01 January 2013
Serum Urate and the Risk of Parkinson's Disease: Results From a Meta-AnalysisIn light of these findings, this study confirms previous findings of a robust association between high serum urate level and PD risk, especially in men. It also suggests that long-term exposure to high serum urate may be linked to the delay of PD progression, however more well-designed investigations are needed. 01 January 2013

Page: [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [+11]

[ « Previous | Next » ]